Can a simple test predict arthritis drug success?
NCT ID NCT06933134
First seen May 07, 2026 · Last updated May 07, 2026
Summary
This study aims to see if a biological marker can predict how well a low dose of the drug rituximab works for people with rheumatoid arthritis. Researchers will enroll 30 adults who already respond well to standard-dose rituximab and switch them to a single 1000 mg dose. By measuring certain blood levels and patient factors, they hope to build a model that forecasts treatment success, potentially allowing for lower doses with fewer side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University hospital
RECRUITINGTours, 37044, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.